α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study
…, W Schulz-Schaeffer, F Sixel-Döring… - The Lancet …, 2011 - thelancet.com
Background Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy
are brain disorders characterised by intracellular α-synuclein deposits. We aimed to assess …
are brain disorders characterised by intracellular α-synuclein deposits. We aimed to assess …
Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects
…, E Trautmann, P Taylor, P Manninger, F Sixel-Döring… - Neuroscience …, 2013 - Elsevier
Several studies demonstrated reduced CSF α-synuclein values in patients with advanced
Parkinson's disease (PD). Values in drug-naïve PD subjects and healthy controls (HC) have …
Parkinson's disease (PD). Values in drug-naïve PD subjects and healthy controls (HC) have …
The nasal and gut microbiome in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorder
…, U Pandey, T Wicke, F Sixel‐Döring… - Movement …, 2018 - Wiley Online Library
Background Increasing evidence connects the gut microbiota and the onset and/or phenotype
of Parkinson's disease (PD). Differences in the abundances of specific bacterial taxa have …
of Parkinson's disease (PD). Differences in the abundances of specific bacterial taxa have …
Monitoring of 30 marker candidates in early Parkinson disease as progression markers
B Mollenhauer, J Zimmermann, F Sixel-Döring… - Neurology, 2016 - AAN Enterprises
Objective: This was a longitudinal single-center cohort study to comprehensively explore
multimodal progression markers for Parkinson disease (PD) in patients with recently diagnosed …
multimodal progression markers for Parkinson disease (PD) in patients with recently diagnosed …
Rapid eye movement sleep behavioral events: a new marker for neurodegeneration in early Parkinson disease?
F Sixel-Döring, E Trautmann, B Mollenhauer… - Sleep, 2014 - academic.oup.com
Objective: To analyze potential markers in sleep for early recognition of neurodegenerative
disease in newly diagnosed, unmedicated patients with Parkinson disease (PD) compared to …
disease in newly diagnosed, unmedicated patients with Parkinson disease (PD) compared to …
The evolution of REM sleep behavior disorder in early Parkinson disease
F Sixel-Döring, J Zimmermann, A Wegener… - Sleep, 2016 - academic.oup.com
Study Objectives: To investigate the development of REM sleep behavior disorder (RBD) and
REM sleep behavioral events (RBE) not yet fulfilling diagnostic criteria for RBD as markers …
REM sleep behavioral events (RBE) not yet fulfilling diagnostic criteria for RBD as markers …
Parkinson's disease sleep scale—validation of the revised version PDSS‐2
Background: The previous Parkinson's disease sleep scale (PDSS) is a 15‐item visual
analogue scale that assesses the profile of nocturnal disturbances in Parkinson's disease (PD) …
analogue scale that assesses the profile of nocturnal disturbances in Parkinson's disease (PD) …
Associated factors for REM sleep behavior disorder in Parkinson disease
F Sixel-Döring, E Trautmann, B Mollenhauer… - Neurology, 2011 - AAN Enterprises
… Sixel-Döring serves/has served on scientific advisory boards for Orion Corporation and
Medtronic, Inc.; has received funding for travel from Boehringer Ingelheim; and has received …
Medtronic, Inc.; has received funding for travel from Boehringer Ingelheim; and has received …
α-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system
…, B Otte, J Ng, A Spreer, P Lange, F Sixel-Döring… - Journal of neural …, 2012 - Springer
The source of Parkinson disease-linked α-synuclein (aSyn) in human cerebrospinal fluid (CSF)
remains unknown. We decided to measure the concentration of aSyn and its gradient in …
remains unknown. We decided to measure the concentration of aSyn and its gradient in …
Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort
B Mollenhauer, E Trautmann, F Sixel-Döring, T Wicke… - Neurology, 2013 - AAN Enterprises
… Sixel-Döring serves/has served on scientific advisory boards for Orion Corporation and
Medtronic, Inc.; has received funding for travel from Boehringer Ingelheim; and has received …
Medtronic, Inc.; has received funding for travel from Boehringer Ingelheim; and has received …
